Each 1g cream contains 0.64mg Betamethasone Dipropionate (equivalent to 0.5mg Betamethasone base).
Mechanism of Action:
Betamethasone preparations contain the dipropionate ester of betamethasone which is a glucocorticoid exhibiting the general properties of corticosteroids.
In pharmacological doses, corticosteroids are used primarily for their anti-inflammatory and/or immune suppressive effects.
Topical corticosteroids such as betamethasone dipropionate are effective in the treatment of a range of dermatoses because of their anti-inflammatory, anti-pruritic and vasoconstrictive actions. However, while the physiologic, pharmacologic and clinical effects of the corticosteroids are well known, the exact mechanisms of their action in each disease are uncertain.
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including vehicle, integrity of the epidermal barrier and the use of occlusive dressings.
Topical corticosteroids can be absorbed through intact, normal skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.
Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids.
Once absorbed through the skin, topical corticosteroids enter pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees, are metabolised primarily in the liver and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted in the bile.
Betamethasone Dipropionate is a synthetic fluorinated corticosteroid. It is active topically and produces a rapid and sustained response in eczema and dermatitis of all types, including atopic eczema, photodermatitis. Lichen planus, lichen simplex, prurigonodularis, discoid lupus erythematosus, necrobiosislipoidica, pretibial myxodemea and erythroderma. It is also effective in the less responsive conditions such as psoriasis of the scalp and chronic plaque psoriasis of the hands and feet, but excluding widespread plaque psoriasis.
Rosacea, acne, perioral dermatitis, perianal and genital pruritus. Hypersensitivity to any of the ingredients of the Betamethasone presentations contra-indicates their use as does tuberculous and most viral lesions of the skin, particularly herpes simplex, vacinia, varicella. Betamethasone should not be used in napkin eruptions, fungal or bacterial skin infections without suitable concomitant anti-infective therapy.
Warnings and precautions:
Dosage and administration:
Adults and Children:
- Once to twice daily. In most cases a thin film of Betamethasone should be applied to cover the affected area twice daily. For some patients adequate maintenance therapy may be achieved with less frequent application.
- Betamethasone Cream is especially appropriate for moist or weeping surfaces.
- lichenifield or scaly lesions but this is not invariably so Control over the dosage regimen may be achieved during intermittent and maintenance therapy by using Betamethasone Cream, the base vehicles of Betamethasone Cream. Such control may be necessary in mild and improving dry skin conditions requiring low dose steroid treatment.
Excessive prolonged use of topical corticosteroids can suppress pituitary-adrenal functions resulting in secondary adrenal insufficiency which is usually reversible. In such cases appropriate symptomatic treatment is indicated. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, reduce the frequency of application, or to substitute a less potent steroid.
The steroid content of each tube is so low as to have little or no toxic effect in the unlikely event of accidental oral ingestion.
Using during pregnancy or lacation:
There are no adequate and well controlled studies of the teratogenic potential of topically applied corticosteroids in pregnant women. Therefore topical steroids should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
It is not known whether topical administration of corticosteroids would result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, a decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother.